Founded in 2013, Eleusis is one of the early movers in the psychedelic medicine space, with a two-pronged approach harnessing psychedelics for both anti-inflammatory and mental health applications.
Eleusis was founded in 2013, and claims to be the first company in the world dedicated to transforming psychedelics into medicines.
We spoke to Shlomi Raz, CEO and Chairman of the Company, about his plans for Eleusis’ future.
WO2019079742A8 | Methods and systems for enhancing safety of psychedelic drug therapies
Priority Date: 2017-10-19 | Status: Published
General Subject Matter: Screening a candidate for treatment with psychedelic agent, including psilocybin
US20200147038A1 | Assessing and treating psychedelic-responsive subjects
Priority Date: 2017-04-20 | Status: Pending in US
General Subject Matter: Improving mental or physical well-being by administration of a psychedelic, including psilocybin